Skip to main navigation Skip to search Skip to main content

Organ transplants of the future: planning for innovations including xenotransplantation

  • Emanuele Cozzi
  • , Stefan Schneeberger
  • , Maria Irene Bellini
  • , Erik Berglund
  • , Georg Böhmig
  • , Kevin Fowler
  • , Martin Hoogduijn
  • , Ina Jochmans
  • , Georg Marckmann
  • , Lorna Marson
  • , James Neuberger
  • , Rainer Oberbauer
  • , Richard N. Pierson
  • , Bruno Reichart
  • , Linda Scobie
  • , Colin White
  • , Maarten Naesens*
  • *Corresponding author for this work
  • Azienda Ospedale - Università Padova
  • Innsbruck Medical University
  • University of Rome La Sapienza
  • San Camillo Hospital
  • Karolinska Institutet
  • Medical University of Vienna
  • KU Leuven
  • Ludwig-Maximilians-Universität München
  • University of Edinburgh
  • Queen Elizabeth University Hospital (Birmingham)
  • Massachusetts General Hospital
  • Klinikum der Universität München
  • Glasgow Caledonian University
  • Irish Kidney Association
  • The voice of the patient

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Scopus)
116 Downloads (Pure)

Abstract

The future clinical application of animal-to-human transplantation (xenotransplantation) is of importance to society as a whole. Favourable preclinical data relevant to cell, tissue and solid organ xenotransplants have been obtained from many animal models utilizing genetic engineering and protocols of pathogen-free husbandry. Findings have reached a tipping point, and xenotransplantation of solid organs is approaching clinical evaluation, the process of which now requires close deliberation. Such discussions include considering when there is sufficient evidence from preclinical animal studies to start first-in-human xenotransplantation trials. The present article is based on evidence and opinions formulated by members of the European Society for Organ Transplantation who are involved in the Transplantation Learning Journey project. The article includes a brief overview of preclinical concepts and biology of solid organ xenotransplantation, discusses the selection of candidates for first-in-human studies and considers requirements for study design and conduct. In addition, the paper emphasizes the need for a regulatory framework for xenotransplantation of solid organs and the essential requirement for input from public and patient stakeholders.

Original languageEnglish
Pages (from-to)2006-2018
Number of pages13
JournalTransplant International
Volume34
Issue number11
Early online date6 Oct 2021
DOIs
Publication statusPublished - Nov 2021

Bibliographical note

for ESOT Workstream 1 of the TLJ (Transplantation Learning Journey) Projec

Funding Information:
MIB, GB, MH, GM, LM, JN, MN, RO, RNP and CW report no conflicts of interest. SS received grants/research support from Novartis, Sandoz, Bridge to Life, Chiesi, Neovii and Organ Recovery; speakers’ bureaux/honoraria from Astellas, Novartis, BMS, Sanofi, OrganOx and Chiesi; and consulting fees from Astellas, Novartis, Teva, Sandoz, Merck, Atara and NefroHealth. EC reports a consulting agreement with Hansa BioPharma. EB is a shareholder in ITB‐MED. KF reports consulting agreements with Hansa BioPharma, Talaris, Otsuka, Palladio Biosciences, Travere Therapeutics, Bayer, Gilead, eGenesis and Veloxis. IJ has received speaker fees from XVIVO Perfusion. BR is CEO of xTransplant. LS is a consulting scientist on safety for XenoTherapeutics and has received funding from MVD Diagnostics for research and development of veterinary diagnostics.

Funding Information: This initiative was supported by the European Society for Organ Transplantation.

Publisher Copyright: © 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd.

© 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd.

Fingerprint

Dive into the research topics of 'Organ transplants of the future: planning for innovations including xenotransplantation'. Together they form a unique fingerprint.

Cite this